Status:
COMPLETED
Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.
Lead Sponsor:
Laboratoires Thea
Conditions:
Purulent Bacterial Conjunctivitis
Eligibility:
All Genders
1-18 years
Phase:
PHASE3
Brief Summary
Efficacy/Safety of T1225, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis of children.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age ≥ one day of life and ≤ 18 years
- Purulent bacterial conjunctivitis
Exclusion
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
286 Patients enrolled
Trial Details
Trial ID
NCT01155999
Start Date
December 1 2008
End Date
February 1 2011
Last Update
October 29 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clermont-Ferrand, France, 63000